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ABSTRACT 
Galanin is a 29 amino acid long neuropeptide. Through interactions with its 
three G-protein coupled receptors, GalR1-GalR3, galanin is involved in several 
functions in the central nervous system, including the regulation of depression-
like behavior and food consumption. As all the three receptor subtypes have 
somewhat different functional binding properties and signaling pathways it has 
been suggested that they have distinct roles in the regulation of various human 
diseases and pathological conditions. This makes GalR1-GalR3 unique 
pharmacological targets. However, due to the lack of subtype specific ligands in 
the galanin field the involvement of different galanin receptors in various 
diseases remains to be determined.  
This thesis is therefore devoted to the development of novel GalR2 subtype 
specific ligands. Additionally, these novel compounds and the functions of 
GalR2 have been investigated in two different behavioral models, namely 
depression-like behavior and feeding regulation.  
Specifically, paper I demonstrates the design of a GalR2 subtype specific 
ligand and a cell line stably expressing GalR3. In papers II and III more GalR2 
subtype specific ligands are introduced and the effect of GalR2 activation on 
food consumption and depression-like behavior is shown, respectively. Paper 
IV shows an approach on how to increase the in vivo usability of peptide 
ligands. In addition, it demonstrates a series of systemically active novel GalR 
ligands with preferential binding to GalR2, including more in-depth 
characterization of one of these peptide ligands. Moreover, in Paper IV the 
attenuate effect of these ligands on depression-like behavior is demonstrated. 
In conclusion, this thesis provides novel strategies for the design of subtype 
specific galanin receptor ligands and introduces a series of them, thereby adding 
additional tools to study the involvement of different galanin receptor subtypes 
in various disorders. In addition, the involvement of GalR2 and its ligands in 
depression-like behavior and in the regulation of food consumption has been 
investigated, and an attenuate effect of several GalR2 agonists on depression-
like behavior has been shown.  
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1. INTRODUCTION  
During the last 30 years the pharmaceutical industry has drawn much attention 
to neuropeptides. Due to the restricted distribution of neuropeptides and their 
receptors it is assumed that drugs acting on neuropeptide receptors might have 
less side effects than classical neurotransmitters. Until now, there are several 
positive examples of drugs for the treatment of chronic diseases targeting  
G-protein coupled receptors (GPCRs). However, finding selective high affinity 
non-peptide agonist or antagonist is challenging, and using peptide based 
compounds as alternatives brings up additional disadvantages, e.g. short half-
life as well as a poor ability to cross the blood-brain barrier (BBB).  
Since the discovery of galanin in 1983, research in this field has been 
hampered by the lack of subtype specific ligands. Modern molecular biology 
and the use of transgenic animals, together with few available ligands, have led 
the field and helped to delineate the galaninergic system so far. However, the 
use of transgenic animals often has drawbacks, e.g. tendency of organisms to 
result in neurochemical compensatory mechanisms when lifelong genetic 
alterations are being made. Therefore, finding pharmacological tools targeting 
neuropeptide receptors is of high interest. Recently, the rational drug design for 
neuropeptide receptors became somewhat easier, as GPCR-ligand co-crystal 
structures are being published. However, none is yet available for any of the 
three galanin receptor subtypes.  
Research described in this thesis aims to address several of these problems 
by designing a series of galanin receptor subtype specific ligands (i–iv), and 
devising an approach to increase in vivo usability of ligands by increasing the 
bioavailability of the peptides in the brain (iv). Furthermore, to test these novel 
subtype specific ligands in different behavioral settings, and thus aiming to 
validate galanin receptor subtypes as potential drug targets. 
 
 
1.1. Neuropeptides 
Neuropeptides are 5–50 amino acids-long neuronal signaling molecules with 
regionally restricted distribution in central and peripheral nervous system. They 
are transmitter molecules used by nerve cells to communicate with each other 
and with peripheral cells. They belong to the wide variety of signaling 
molecules that compose the nervous system. 
The first neuropeptide, Substance P, was discovered in 1931 by Euler and 
Gaddum. However, its sequence was not identified until 40 years later. The 
identification of neuropeptides accelerated when Victor Mutt and colleagues 
started focusing on the isolation of C-terminally amidated peptides, thus leading 
to the discovery of numerous neuropeptides, including galanin, glucagon, 
secretin, NPY. The field expanded even more following the sequencing of  
G-protein coupled receptors (GPCRs) by homology cloning. Since many of the 
4
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endogenous ligands for the GPCRs were not known, they became a hot drug 
target for the pharmaceutical industry. This phenomenon was amplified after the 
Human Genome Project detected numerous GPCR sequences without any 
knowledge of their endogenous ligands. The majority of neuropeptide receptors 
belong to GPCRs family, the largest known family of membrane-bound 
receptors, often also referred to as seven-transmembrane receptors (7TM) which 
currently constitute one of the favorite classes of drug targets for the pharma-
ceutical industry.  
Neuropeptides exhibit several important differences from classical neuro-
transmitters. In contrast to neurotransmitters, which are synthesized in nerve 
terminals, neuropeptides are produced as ribosomal pre-prohormones. These 
constructs are to be cleaved and often post-translationally modified by ami-
dation, acetylation, phosphorylation, sulfation, and glycosylation. A single 
neuropeptide precursor molecule can give rise to more than one biologically 
active peptide, e.g. multiple copies of a single neuropeptide, multiple different 
neuropeptides or any combination of these. Additionally, the signaling of the 
low molecular weight neurotransmitters and neuropeptides is somewhat 
different, since classical neurotransmitters are more widely distributed. There-
fore, drugs targeting neuropeptide receptors are hypothesized to be more selec-
tive and thus have fewer side effects than the drugs acting on classical neuro-
transmitter systems. Furthermore, bioactive neuropeptides are released from 
large dense-core vesicles (LDCV) derived from the trans-Golgi network, 
whereas the vast majority of classical neurotransmitters are released from small 
synaptic vesicles (SSV) that are clustered in the synaptic zones. In contrast, 
LDCVs are more diffusely scattered around the nerve terminals, wherefore the 
release of neuropeptides from LDCVs generally requires higher stimulation or 
specific stimulation patterns. SSVs on the other hand can be released by focal 
increase of calcium in the synaptic zone. Opposite to classical neuro-
transmitters, no reuptake mechanism is known for neuropeptides, LDCVs can 
only be used once. Thereafter, the peptides are cleaved and their activity is 
terminated by extracellular peptidases. On the other hand their postsynaptic 
effect usually lasts longer than that of the classical neurotransmitters.  
Taken together, neuropeptides are molecules that possess a wide spectrum of 
functions (ranging from neurotransmitter to growth factor), and are of particular 
importance when the nervous system is challenged. Today, the development of 
receptor subtype specific ligands for neuropeptide receptors as potential drug 
candidates or tools to validate GPCRs as drug targets is of high interest.  
 
 
1.2. The galanin family 
Thirty years have passed since the discovery of neuropeptide galanin. During 
this time three additional bioactive members of the galanin family have been 
described. Furthermore, three GPCRs that have shown to interact with members 
of the galanin family have been identified.  
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1.2.1. Galanin 
Galanin was discovered by Professor Viktor Mutt and colleagues using a 
chemical technique for the detection of amidated peptides at the Karolinska 
Institute in 1983. The 29 amino acid long neuropeptide was identified from 
porcine upper intestinal extracts and named galanin after its N-terminal glycine 
and C-terminal alanine residue (Tatemoto et al. 1983). Galanin is C-terminally 
amidated peptide in most species it has been identified from. Only in humans 
and macaques is galanin 30 amino acids long and has a C-terminal free 
carboxylic acid (Table 1).The N-terminal 1–15 amino acids of galanin are 
conserved in all species, except tuna, where two amino acid residues are 
substituted (Kakuyama et al. 1997). All the differences are situated in the  
C-terminal region of the peptide. Concordantly, studies have shown that the  
N-terminal end of galanin is crucial for the biological activity of the peptide, 
while the C-terminal part is suggested to sterically protect the N-terminal part of 
the peptide from proteolytic degradation. Comparison of the half-lives of 
galanin and galanin(1–16) resulted in approximately 3–4 longer time in favor of 
the entire molecule when measured in membrane suspensions of rat hypo-
thalamus, spinal cord, and in rat cerebrospinal fluid (CSF) (Bedecs et al. 1995, 
Land et al. 1991a, Land et al. 1991b). In solution, galanin forms a horseshoe-
like conformation consisting of two α-helical structures interrupted by a β-bend 
around the Proline in position 13 (Ohman et al. 1998).  
Galanin is expressed as a 123 (porcine, bowine and human) and 124 (mouse 
and rat) amino acid precursor protein called preprogalanin. The propeptide is 
composed of the N-terminal signal peptide sequence, galanin, and C-terminal 
59/60 amino acids long flanking peptide called Galanin Message Associated 
Peptide (GMAP). Galanin is flanked by tryptic dibasic cleavage sites (Lys-Arg), 
separating it from its neighbors, the N-terminal signal peptide and GMAP 
(Rökaeus & Brownstein 1986). As mentioned previously, human and macaque 
galanin sequences are unique. They differ from all the others due to the single 
base mutation yielding a Ser in the place of the Gly residue. This substitution 
results in the C-terminal carboxylic acid, in contrast to galanin from other 
species, where Gly serves as an amide donor (Cunningham et al. 2002, Evans & 
Shine 1991). The human galanin gene is localized on chromosome 11 at 
position q13.3–q13.5. The gene spans 6.5 kb and consists of 6 exons which are 
translated into the 0.9 kb long message (Evans et al. 1993). 
Galanin is widely expressed in central and peripheral nervous systems as 
well as in endocrine system of various species, including humans. Its mRNA 
and galanin-immunoreactivity are distributed throughout the central nervous 
system (CNS), where it has been mainly identified in hypothalamus, thalamus, 
ventral hippocampus, locus coerules, midbrain, basal forebrain, medulla 
oblongata, and in the pituitary (Merchenthaler et al. 1993). Furthermore, galanin 
is known to coexist with other neuropeptides, such as NPY, enkephaline, 
substance P, vasopressin, calcitonin gene related peptide, and with numerous of 
classical neurotransmitters like dopamine, serotonin, noradrenaline, ACh, and 
16 
 
GABA (Zhang et al. 1998, Zhang et al. 1995, Melander et al. 1986, Miller et al. 
1998). 
 
Table 1. Endogenously occurring galanin sequences from different species 
Species Sequence Reference 
Human  GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS (Schmidt et al. 
1991) 
Macaque GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS (Cunningham et al. 
2002) 
Porcine GWTLNSAGYLLGPHAIDSHRSFHDKYGLA-amide (Tatemoto et al. 
1983) 
Bovine GWTLNSAGYLLGPHALDNHRSFQDKHGLA-amide (Rökaeus et al. 
1988) 
Dog GWTLNSAGYLLGPHAIDNHRSFHEKPGLT-amide (Boyle et al. 1994) 
Sheep GWTLNSAGYLLGPHAIDNHRSFHDKHGLA-amide (Sillard et al. 
1991) 
Rat GWTLNSAGYLLGPHAIDNHRSFSDKHGLT-amide (Kaplan et al. 
1988a) 
Mouse GWTLNSAGYLLGPHAIDNHRSFSDKHGLT-amide (Lundkvist et al. 
1995) 
Chicken GWTLNSAGYLLGPHAVDNHRSFNDKHGFT-amide (Norberg et al. 
1991) 
Quail GWTLNSAGYLLGPHAVDNHRSFNDKHGFT-amide (Tsutsui et al. 
1998) 
Alligator GWTLNSAGYLLGPHAIDNHRSFNEKHGIA-amide (Wang & Conlon 
1994b) 
Frog GWTLNSAGYLLGPHAIDNHRSFNDKHGLA-amide (Chartrel et al. 
1995) 
Tuna GWTLNAAGYLLGPHGIDGHRTLGDKPGLA-amide (Habu et al. 1994) 
Trout GWTLNSAGYLLGPHGIDGHRTLSDKHGLA-amide (Anglade et al. 
1994) 
Turtle GWTLNSAGYLLGPHAVDNHRSLIDLHGLA-amide (Wang et al. 1999) 
Bowfin GWTLNSAGYLLGPHAVDNHRSLNDKHGLA-amide (Wang & Conlon 
1994a) 
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1.2.2. Galanin message associated peptide (GMAP) 
GMAP is the least studied member of the galanin family. The sequence of 
GMAP shows high degree of homology between species, although not to the 
same extent as galanin (Table 2) (Lundkvist et al. 1995). As expected, the study 
comparing GMAP- and galanin-like immunoreactivities in the brain 
demonstrated that the GMAP distribution generally overlaps with that of 
galanin (Hökfelt et al. 1992). 
Previous research on several different nociception models has shown that 
GMAP has pharmacological actions in spinal nociceptive transmission in rat 
spinal cord (Bartfai et al. 1991, Xu et al. 1995a, Xu et al. 1995b, Andell-
Jonsson et al. 1997, Hao et al. 1999). Recently, interesting studies from Holub 
and Rauch have demonstrated that GMAP exhibits antifungal activity. A study 
from 2007 indicates a role of GMAP as a possible new component of the innate 
immune system. In this publication its inhibitory actions on the growth of 
Candida albicans as well as on the transition of budded-to-hyphal-form has 
been demonstrated (Rauch et al. 2007). In a recent study, Holub et al. showed 
that GMAP was able to reduce the growth of six out of seven Candida strains 
(Holub et al. 2011), suggesting therapeutic potential of GMAP as a common 
antifungal substance. 
 
Table 2. Endogenously occurring GMAP sequences from different species 
Species Sequence Reference 
Human ELRPEDDMKPGSFDRSIPENNIMRTIIEFLSFHLK
EAGALDRLLDLPAAASSEDIERS  
(Evans & Shine 1991) 
Cow ELEPEDEARPGSFDRPLAENNVVRTIIEFLTFLH
LKDAGALERLPSLPTAESAEDAERS  
(Rökaeus & 
Brownstein 1986) 
Rat ELPLEVEEGRLGSVAVPLPESNIVRTIMEFLSFL
HLKEAGALDSLGIPLATSSEDLEQS  
(Kaplan et al. 1988b) 
Mouse ELQLEVEERRPGSVDVPLPESNIVRTIMEFLSFL
HLKEAGALDSLGIPLATSSEDLEKS  
(Lundkvist et al. 
1995) 
Pig ELEPEDEARPGGFDRLQSEDKAIRTIMEFLAFLH
LKEAGALGRLPGLPSAASSEDAGQS  
(Lundkvist et al. 
1995) 
 
 
1.2.3. Galanin-like peptide (GALP) 
In 1991, the third member of the galanin family, galanin-like peptide (GALP), 
was isolated from porcine hypothalamus by Ohtaki and colleagues. The 60 
amino acid long peptide with non-amidated C-terminus was discovered while 
searching for endogenous ligands capable to induce GTP-binding to a 
membrane preparation of GalR2-transfected cells (Ohtaki et al. 1999).  
5 
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The amino acid sequence of GALP (9–21) is identical with the N-terminal 
13 residues of galanin, which are known to be conserved in numerous of species 
and of high importance for the biological activity of galanin. Competitive 
binding studies with porcine GALP demonstrated its preferential binding (20 
times) towards GalR2, when compared to GalR1. In addition, GTPγS binding 
assay was used to demonstrate porcine GALP agonistic properties (Ohtaki et al. 
1999). However, the latest competitive binding studies using human GALP with 
[125I]-galanin showed that GalR3 binds GALP with the highest affinity (Lang et 
al. 2005). 
Analysing the human genome revealed that GALP gene shares a marked 
degree of similarity with human galanin gene. Both genes are comprised of 6 
exons, in which the first is noncoding. Human GALP is located on chromosome 
19 (human galanin on chromosome 11) and similarly to preprogalanin, it is 
encoded by exons 2–6 to a precursor protein. PreproGALP is 115–120 amino 
acid residues long, varies in different species (Table 3), and is cleaved into 
GALP peptide (Ohtaki et al. 1999, Cunningham et al. 2002). 
 
Table 3. Endogenously occurring GALP sequences from different species 
Species Sequence Reference 
Human APAHRGRGGWTLNSAGYLLGPVLHLPQMGDQ
DGKRETALEILDLWKAIDGLPYAHPPQPS 
(Ohtaki et al. 1999) 
Macaque APAHQGRGGWTLNSAGYLLGPVLHLPQMGDQ
DRKRETALEILDLWKAIDGLPYSHPLQPS 
(Cunningham et al. 
2002) 
Rat APAHRGRGGWTLNSAGYLLGPVLHLSSKANQ
GRKTDSALEILDLWKAIDGLPYSRSPRMT 
(Ohtaki et al. 1999) 
Mouse APAHRGRGGWTLNSAGYLLGPVLPVSSKADQG
RKRDSALEILDLWKIIDGLPYSHSPRMT 
(Juréus et al. 2001) 
Pig APVHRGRGGWTLNSAGYLLGPVLHPPSRAEGG
GKGKTALGILDLWKIDGLPYPQSQLAS 
(Ohtaki et al. 1999) 
 
 
In contrast to galanin, the distribution of GALP across species is limited. 
Markable differences in terms of expression patterns/magnitude might be due to 
the fact that galanin is more widely expressed in the brain than GALP. In situ 
hybridization analysis of rat, mouse, and macaque have revealed cells 
expressing GALP mRNA to be found in the arcuate nucleus (Arc), median 
eminence, infundibular stalk, caudal part of the dorsomedial nucleus and in the 
pituitary (Cunningham et al. 2002, Juréus et al. 2000, Takatsu et al. 2001). In 
addition, GALP containing fibers have been predominantly found in 
hypothalamic paraventricular nucleus, medial preoptic area, the bed nucleus of 
the striaterminalis, and the lateral septal nucleus (Takatsu et al. 2001).  
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GALP, similarly to galanin, has been shown to be involved in feeding 
behavior and energy balance. It has short-term orexinergic actions in rats, while 
in long term it reduces bodyweight and stimulates thermogenesis in rodents. 
Recent data suggest that long term actions are mediated trough GALP induced 
expression of Il-1 in the brain. In IL-1α/β-, IL-1β-, or IL-1 type I receptor (IL-
1RI)-deficient mice the effects of GALP on feeding, body weight, and body 
temperature are significantly reduced. Similar effects of GALP were seen when 
co-administered with IL-1 receptor antagonist (Man & Lawrence 2008). The 
short-term increased food intake induced by GALP is mediated via orexin and 
NPY (Kageyama et al. 2006, Kuramochi et al. 2006).  
Several studies have suggested that GALP does not exclusively interact with 
galanin receptors. It has been shown that similarly to wild type mice, GALP 
also induces weight loss and food intake reduction in both, GalR1 and GalR2- 
deficient mice. In addition, GalR2/GalR3 agonist (AR-M1896) does not have 
any effect on food intake or body weight in rat and mouse (Krasnow et al. 
2004). All this suggests that there might be an unidentified GALP binding 
receptor.  
 
 
1.2.4. Alarin 
The most recent member of the galanin family, alarin, is named after its  
N-terminal alanin and C-terminal serine and was identified in 2006 (Santic et al. 
2006). The 25 amino acids long neuropeptide is encoded from an alternative 
transcript of GALP mRNA, which misses exon 3 resulting in a frame shift of 
the GALP mRNA sequence. It has been shown that Alarin shares very little 
homology with mature GALP, only the first 5 amino acids are identical. 
Homology with any other murine peptide, including galanin, has not been 
detected (Santic et al. 2006). Unlike GALP and galanin, alarin lacks the galanin 
receptor binding domain and thus doesn`t have any binding affinity towards any 
of the three galanin receptor subtypes (Boughton et al. 2010). The sequence 
identity of alarin between rat and mice is 88%, between human and macaque 
96%, while between rodent and primate only 60% (Table 4) (Santic et al. 2007). 
However, similarly to galanin, the N-terminal part of alarin shares homology 
between all the different species, and therefore, it is suggested that the N-
terminal part might be crucial for the receptor binding (Santic et al. 2007). This 
phenomena is somewhat proven by Fraley and colleagues, who demonstrate that 
removal of several N-terminal amino acids of alarin eliminates its ability to 
stimulate food consumption and plasma LH secretion (Fraley et al. 2012b). 
However, this study also shows that i.c.v. injected Ala6-25Cys leads to a 
significant reduction in circulating LH levels and co-administration of it with 
Ala1-25 prevents the increase in 24 h body weight, suggesting the antagonistic 
properties of Ala6-25Cys (Fraley et al. 2012b).  
Alarin expression has been reported in murine brain, thymus, and skin 
(Santic et al. 2007), human neuroblastic tumors and human skin (Santic et al. 
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2007, Santic et al. 2006). Additionally, a recent study has demonstrated the 
distribution of alarin-like immunoreactivity (alarin-LI) in rodents’ brain more in 
detail. In CNS of mice, alarin-LI was widely distributed throughout the brain, 
showing high intensity in the mitral cell layer of the olfactory bulb, the 
accessory olfactory bulb, the medial preoptic area, different nuclei of the 
hypothalamus such as the arcuate nucleus and the ventromedial hypothalamic 
nucleus, the locus coeruleus, the ventral cochlear nucleus, and the facial nucleus 
and the epithelial layer of the plexus choroideus (Eberhard et al. 2012).  
 
Table 4. Endogenously occurring alarin sequences from different species 
Species Sequence Reference 
Human APAHRSSTFPKWVTKTERGRQPLRS (Santic et al. 2006) 
Rat APAHRSSTFPQRPTRAGRQTQLLRS (Santic et al. 2007) 
Mouse APAHRSSPFPPRPTRAGRETQLLRS (Santic et al. 2007) 
Macaque APAHRSSTFPKWVTKTGRGRQPLRS (Santic et al. 2007) 
 
 
Similarly to galanin and GALP, alarin has shown to regulate feeding. Recent 
research has demonstrated that central administration of alarin increases acute 
food consumption, while no effect was seen on food intake after 24 h (Fraley et 
al. 2012a, Fraley et al. 2012b, Van Der Kolk et al. 2010, Boughton et al. 2010). 
Interestingly, the relative bodyweight was shown to be significantly increased 
after 24 h (Fraley et al. 2012a). In addition, i.c.v. injected alarin significantly 
increases plasma leutizing hormone (LH)-level in a gonadotrophin-releasing 
hormone (GnRH)-mediated manner (Fraley et al. 2012a, Boughton et al. 2010, 
Van Der Kolk et al. 2010). Unlike galanin and GALP, alarin has been shown to 
have no effect on body temperature or on male sex behaviors in rodents (Van 
Der Kolk et al. 2010, Fraley et al. 2012a).  
 
 
1.3. Galanin receptors 
The biological activity of galanin is mediated through three galanin receptor 
subtypes, GalR1, GalR2, and GalR3. All of them are members of G-protein-
coupled receptors superfamily and exhibit high binding affinity towards 
galanin. However, they (GalR1-GalR3) have somewhat different functional 
binding properties and signaling pathways, which makes` them a great target for 
the treatment of various human diseases and pathological conditions.  
 
 
 
 
21 
1.3.1. Galanin receptor subtype 1 
The first known galanin receptor, GalR1, was cloned from human Bowes 
melanoma cells (Habert-Ortoli et al. 1994). The gene for GalR1 is comprised of 
3 exons, which in mouse and human are translated into a 348 and 349 amino 
acid long proteins, respectively. The homology between species is high, human 
and mouse GalR1 share 93% identity in the amino acid sequence level (Jacoby 
et al. 1997). The highest residual similarity has been detected between GalR1 
and GalR2 (42%) as well as GalR3 (38%). 
GalR1 mRNA distribution determination with RT-PCR showed its exclusive 
expression in the CNS and peripheral nervous system (PNS), where it was 
detected in hippocampus, hypothalamus, cortex, amygdala, spinal cord, and 
dorsal root ganglia (Waters & Krause 2000). 
GalR1 is coupled to Gαi/o. Its activation leads to inhibition of forskolin-
stimulated cAMP production in a pertussistoxin (PTX)-sensitive manner (Wang 
et al. 1998, Habert-Ortoli et al. 1994, Waters & Krause 2000), which in turn 
leads to the opening of the G-protein-regulated inwardly rectifying K+ (GIRK) 
channels (Lang et al. 2007). Furthermore, GalR1 stimulation increases PTX 
sensitive MAPK activity in a PKC independent manner (Wang et al. 1998). 
 
 
1.3.2. Galanin receptor subtype 2 
The second galanin receptor, GalR2, was identified from rat hypothalamus 
(Ahmad et al. 1998, Howard et al. 1997, Smith et al. 1997). The 387 amino acid 
protein is translated from the human GalR2 gene, which is comprised of 2 
exons. As GalR1, the human GalR2 also has high sequence identity (87%) and 
similarity (92%) with rat GalR2 (Kolakowski et al. 1998). Studies show that the 
distribution of GalR2 is more wide spread in CNS and PNS than that of GalR1. 
High levels of GalR2 mRNA have been detected in hippocampus, 
hypothalamus, cortex, amygdala, spinal cord, DRG, anterior pituitary, lung, and 
kidney, while lower levels were seen in large intestine, spleen, heart, and liver 
(Waters & Krause 2000, Kolakowski et al. 1998).  
In contrast to other galanin receptors, GalR2 signals through multiple classes 
of G proteins. Most commonly GalR2 acts through Gαq/11. This pathway 
activates phosphilipase C (PLC) and leads to increased intracellular 
phosphoinositol release, mediating the release of Ca2+ into the cytoplasm from 
intracellular stores and opening Ca2+-dependent channels (Kolakowski et al. 
1998, Smith et al. 1997, Wang et al. 1998). GalR2 is also shown to couple to 
Gαo-type G-protein and stimulate MAPK activity in protein kinase C (PKC) 
dependent, PTX-sensitive fashion (Wang et al. 1998). GalR2 is also proposed to 
activate RhoA in small lung cancer cells via coupling to G12/13-type G-protein 
and enhance neuronal survival by suppressing caspase-3 and caspase-9 activity 
(Wittau et al. 2000, Ding et al. 2006). In several cell lines GalR2, similar to 
GalR1, has shown to inhibit adenylcyclase activity in a PTX-sensitive manner, 
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suggesting the activation of Gαi/αo types of G-proteins (Wang et al. 1998). Both 
GalR1 and GalR2 inhibit cyclic AMP-responsive element –binding (CREB) 
protein (Badie-Mahdavi et al. 2005). 
 
 
1.3.3. Galanin receptor subtype 3 
The third galanin receptor subtype, GalR3, was cloned from rat hypothalamic 
cDNA libraries (Wang et al. 1997a). The GalR3 gene is divided into two exons, 
which are translated into a 368 amino acid long protein (Kolakowski et al. 1998). 
The human GalR1 protein shares 36% and 58% homology with human GalR1 
and GalR2, respectively, and 89% with rat GalR3 (Kolakowski et al. 1998). 
GalR3 is suggested to have a more restricted expression pattern when com-
pared to other two galanin receptors. Highest levels of GalR3 mRNA have been 
detected in the preoptic/hypothalamic area and in the subfornical organ (Men-
nicken et al. 2002). However, other studies report a wider distribution of GalR3 
throughout the CNS and PNS (Wang et al. 1997a, Kolakowski et al. 1998).  
Signaling properties of GalR3 are still vague. Similarly to GalR1, GalR3 
appears to couple to Gi/o-type G-protein and inhibit AC, resulting in the opening 
of GIRK channels (Kolakowski et al. 1998, Smith et al. 1998). 
 
 
1.4. Biological effects of galanin 
Galanin is regulating numerous of pathological and physiological processes, 
including mood disorder, anxiety, alcohol intake in addiction, metabolic 
diseases, pain, and is expressed in some solid tumors through three different G-
protein coupled receptors (Kyrkouli et al. 1986, Wiesenfeld-Hallin et al. 2005, 
Berger et al. 2004, Rada et al. 2004, Holmes et al. 2003b, Kuteeva et al. 2008a, 
Rodriguez-Puertas et al. 1997). The current study is focusing on the biological 
effects of galanin in two behavioral models, namely depression-like behavior 
and feeding.  
 
 
1.4.1. Mood disorders and depression 
Depression is estimated to be the fourth major cause of disability, affecting 
about 121 million people worldwide (Mathers et al. 2000, WFMH 2010). The 
lifetime prevalence of depressive episodes is estimated to be about 20% for men 
and 10% for women (DSM-IV 2000). Reduced social and work functions, 
indecisiveness, disturbance of sleep, reduced physical functions, low mood, 
feeling of hopelessness and worthlessness, sexual dysfunctions, and impairment 
of learning and memory, among many other symptoms have been related to 
mood disorders (Montgomery 2006, Clark et al. 2009, Eriksson et al. 2011). 
These abnormalities often result in reduced ability to work, pursuing personal 
interests and maintaining relationships. US workers suffering from major 
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depression were estimated to cause 36.6 billion dollars salary-equivalent 
productivity and 225.0 workdays lost per year (Kessler et al. 2006). Depression 
can cause serious consequences for the affected person and also to her/his 
family. It has been shown that around 60% of people who commit suicide have 
suffered from depression or from another mood disorder (Clark et al. 2009). 
However, despite all the serious consequences, less than 50% of all patients 
treated with currently available antidepressants show full remission (Crisafulli 
et al. 2011). 
Understanding the aetiology of depression is still somewhat limited due its 
clinical heterogeneity. The most popular theory of depression, “the Monoamine 
Hypothesis” (Schildkraut 1965), has dominated this research field. It states that 
depression is the result of monoamines underactivity. NA and 5-HT are 
believed to be monoaminergic systems that are involved in the pathogenesis of 
mood disorders (Heninger et al. 1996, Weiss et al. 1981).  
 
 
1.4.2. Galanin and depression-like behavior 
Neuropeptides, including galanin, have been shown to play an important role in 
the regulation of mood disorders (Holmes et al. 2003a). Galanin is known to be 
co-localized with NA in LC and with 5-HT in dorsal raphe nucleus (DR). As 
mentioned above, both NA and 5-HT are implicated in the regulation of these 
disorders (Schildkraut 1965, Pieribone et al. 1995, Xu et al. 1998, Ma et al. 
2001, Weiss et al. 1981, Heninger et al. 1996). Galanin has been shown to 
regulate serotonergic and noradrenergic system by having inhibitory actions on 
5-HT/DR and NA/LC neurons (Pieribone et al. 1995, Xu et al. 1998, Ma et al. 
2001). Inhibitory effects on noradrenergic system are supposedly mediated 
through GalR1/GalR3. The electrophysiological analysis using GalR1/2 agonist 
AR-M961 and GalR2 agonist AR-M1896 demonstrated that inhibition of firing 
and hyperpolarization of LC neurons is caused only by the GalR1/2 agonist, and 
not by the GalR2 agonist (Ma et al. 2001). 
Modulation of serotonergic system is suggested to be similar to that of 
noradrenergic. Study using GalR2 agonist M1896 demonstrated that activation 
of GalR2 leads to increased 5-HT release, while GalR3 antagonist SNAP 37889 
partially blocked the effect of i.c.v. injected galanin. Therefore, the inhibitory 
actions of galanin on serotonergic system are most likely mediated trough 
GalR1 and GalR3, whereas activation of GalR2 stimulates 5-HT release.  
Accordingly, research using galanin receptor subtype specific ligands has 
demonstrated that GalR2 agonist AR-M1896 and systemically active GalR3 
antagonist SNAP 37889 decreased immobility time in forced swim test (FST), 
while GalR2 antagonist M871, similarly with GalR1 agonist M617, had an 
opposite effect. Thus, suggesting that activation of GalR1 and GalR3 results in 
a depression like behavior, while stimulation of GalR2 leads to attenuation of 
the same disorder (Kuteeva et al. 2008b, Lu et al. 2005a, Swanson et al. 2005b, 
Barr et al. 2006). 
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1.4.3. Energy homeostasis 
Energy homeostasis is a process in which the brain regulates the intake and the 
expenditure of the energy. This process is regulated by a complex endocrine 
system which includes both centrally and peripherally expressed peptides. 
Neuropeptides, that are involved in regulation of appetite, can be divided to 
orexigenic (appetite-stimulating) and anorectic peptides. NPY, melanin 
concentrating hormone (MCH), orexins A and B, agouti – related peptides, and 
galanin are known to stimulate food consumption, while alpha-melanocyte 
stimulating hormone (αMSH), corticotropin releasing hormone (CRH), 
cholecystokinin (CCK), cocaine and amphetamine regulated transcript (CART), 
neurotensin, glucagon-like peptide 1 (GLP 1), and bombesin are known to have 
anorectic actions (Tritos & Maratos-Flier 1999, Hillebrand et al. 2002). There-
fore, understanding the central and peripheral factors of energy homeostasis 
might lead to effective treatments to control obesity, one of the leading causes 
of preventable death in western countries.  
 
 
1.4.4. Galanin and feeding 
Galanin plays a critical role in regulation of energy homeostasis. Direct 
administration of galanin into the lateral ventricle and the paraventricular 
nucleus (PVN) has been shown to robustly stimulate feeding in rodents 
(Crawley et al. 1990, Kyrkouli et al. 1986). The effect is higher in rodents fed 
with high fat diet than with regular diets (Tempel et al. 1988). In addition, a 
similar effect of galanin has also been detected in goldfish and chicks 
(Tachibana et al. 2008, de Pedro et al. 1995), suggesting that the orexigenic 
mechanism of galanin is conserved beyond animal species. Chronic 
administration of galanin to PVN resulted in the significant increase in daily 
calorie intake and body weight (Yun et al. 2005). Similar effect, increased fat-
rich diet consumption (by 55%), has also been detected in galanin over 
expressing mice; while galanin knockout (KO) mice showed a decrease in fat 
rich diet ingestion (by 48%) (Karatayev et al. 2009, Karatayev et al. 2010). 
Furthermore, Adams and colleagues demonstrated that chronic administration 
of galanin by mini-osmotic pumps into lateral ventricle of galanin KO mice 
partially reversed the fat avoidance phenotype (Adams et al. 2008). Moreover, 
PVN injections of M40 (galanin receptor antagonist) decreased the intake of fat-
rich diet (Leibowitz & Kim 1992), whereas co-administration of galanin 
antagonist with galanin blocked the galanin induced feeding effect (Corwin et 
al. 1993). Similarly, chronic PVN injections of antisense oligonucleotides to 
GAL mRNA in rats significantly reduced the daily intake of fat and weight gain 
(Akabayashi et al. 1994). However, previous research has shown that 
exogenous galanin only stimulates food consumption when food is readily 
available (Anderson et al. 2012). Taken together, these data indicate that 
galanin promotes overeating and weight gain by regulating fat intake when food 
is freely accessible.  
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Galanin is known to coexist with NA in brain of rats, including PVN, the 
region that is sensitive to galanin's stimulatory effect on feeding (Kyrkouli et al. 
1990, Melander et al. 1986). Pharmacological studies using α2-receptors 
blockers have shown to attenuate galanin induced feeding response in rodents 
(Kyrkouli et al. 1990) as well as in goldfish and chicks (de Pedro et al. 1995, 
Tachibana et al. 2008). Similar effect has been demonstrated using an opioid 
receptor antagonist naloxone (highest affinity towards µ-receptor), which 
reduced feeding evoked by i.c.v. administered galanin (Barton et al. 1995, Dube 
et al. 1994). Therefore, the orexigenic effect of galanin is suggested to be 
related to α2-receptor and opioid µ-receptor. 
Several studies indicate that leptin reduces galanin mRNA levels in PVN 
and thereby suppresses galanin induced food intake (Cheung et al. 2001, Sahu 
1998), while the sensitivity of body weight and fat tissue to leptin is inhibited 
by galanin (Hohmann et al. 2003).  
Evidence suggests that GALP, similarly to galanin, also stimulates feeding 
and gain in body weight. Although, the orexigenic action of i.c.v. injected 
GALP in rats is short, stimulating feeding only over the first hour, whereas in 
mice it had no effect (Seth et al. 2003). After 24h GALP reduced the food 
intake and body weight in both, mice and rats, while similar response was not 
seen when GalR2/3 agonist was administered. Thus, suggesting that GALP 
mechanism of action on feeding regulation might be partly independent of 
GalR1–3, and it may have its specific receptor that is not yet determined.  
 
 
1.5. Galanin receptor ligands 
All three galanin receptor subtypes, GalR1 – GalR3, are known to have 
somewhat different binding and signaling properties. Endogenous galanin is 
known to bind with a high affinity and act as an agonist on all three of them. 
Therefore, finding subtype specific ligands is of great interest in galanin field. 
However, despite the urgent need there are only few workable compounds 
available. 
To date, the developed galanin ligands can be classified by their structure 
(peptide ligands and non-peptide ligands), by their ability to activate the 
receptor (agonist, antagonist or allosteric modulators), as well as by their ability 
to penetrate BBB.  
 
 
1.5.1. Peptide ligands 
In addition to endogenous galanin, several truncated galanin fragments are 
available (Table 5) (Wang et al. 1997b). Galanin fragment Gal(1–16) has shown 
to retain high affinity towards galanin receptors and to be highly efficient 
agonist both in vitro and in vivo (Wang et al. 1997b, Lu et al. 2005c).  
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A widely used peptide ligand ARM1896 (Gal (2–11)) was first published as 
GalR2 subtype specific agonist by Liu and colleagues in 2001 (Liu et al. 2001). 
However, they did not test it on GalR3 and following publications have shown 
that ARM1896 binds to GalR3 with a similar affinity as to GalR2 (Lu et al. 
2005b).  
The fact that GalR1 does not tolerate deletions on the N-terminal part of the 
galanin peptide has been used to design several other galanin fragments having 
preferential binding towards GalR2 when compared to GalR1 (Table 5) (Wang 
et al. 1997b). 
Another endogenously occurring peptide, galanin-like peptide (GALP), was 
first demonstrated as a high affinity agonist for GalR1 and GalR2 with a 20 
times better affinity towards GalR2 (Ohtaki et al. 1999). However, a recent 
study testing the binding affinity of GALP on all three galanin receptors showed 
that instead of GalR2 GALP has more than 10 times preferential binding 
towards GalR3 (Boughton et al. 2010). 
 
Table 5. Affinities of galanin, GALP, and their fragments on three galanin receptor 
subtypes 
Name GalR1 Ki (nM) 
GalR2 
GalR3 Reference 
Rat galanin(1–29) 1.0 1.5 1.5 (Wang et al. 1997b) 
 0.3 (h) 1.6 (h) 12 (h) (Borowsky et al. 1998) 
 0.9 (h) 1.2 (h) 7.4 (h) (Lu et al. 2005c) 
Human galanin(1–30) 0.4 (h) 2.3 (h) 69 (h) (Borowsky et al. 1998) 
Porcine galanin(1–29) 0.23 (h) 0.95 (h) 9.8 (h) (Borowsky et al. 1998) 
Galanin(1–16) 4.8 5.7 50 (Wang et al. 1997b) 
Galanin(2–29) 85 1.9 12 (Wang et al. 1997b) 
Galanin(3–29) >1000 >1000 >1000 (Wang et al. 1997b) 
Galanin(2–11) >5000 (h) 88 271 (Lu et al. 2005b) 
Porcine GALP 4.3 0.24 – (Ohtaki et al. 1999) 
Human GALP 77 a (h) 28 a (h) 10 a (h) (Lang et al. 2005) 
Human GALP(1–32) 129 69 – (Lang et al. 2005) 
Human GALP(3–32) 33 15 – (Lang et al. 2005) 
Rat GALP 45 a 18.7 a 1.53 (h) a (Boughton et al. 2010) 
Displacement is performed on the rat galanin receptor unless indicated otherwise.  
(h) human; a presented as IC50 values; – not determined. 
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There are also several chimeric peptide ligands available. M15 (Bartfai et al. 
1991), M35 (Ögren et al. 1992), C7, and M40 (Crawley et al. 1993) are all 
high-affinity galanin receptor antagonists. Although, when delivered i.c.v. or 
intrathecally (i.t.) at doses higher than 10 nmol all these ligands are known to 
have partial agonistic nature (Kask et al. 1995, Bartfai et al. 1993, Lu et al. 
2005c). At lower doses (0.1 to 10 nmol), when delivered i.c.v. or i.t, they 
maintained their antagonistic properties (Lu et al. 2005c).  
M15, often referred as galantide, was the first antagonist in the galanin field. 
This chimeric peptide ligand is composed of N-terminal galanin (1–13) 
fragment and of C-terminal substance P (5–11) fragment (Table 6–7). 
Displacement studies on the membranes from the rat tissues demonstrated 
around 10-fold higher affinity of M15 than endogenous galanin (Bartfai et al. 
1991). However, M15 was chemically unstable and therefore a series of 
chemically more stable galanin receptor agonist were developed. Later binding 
studies have revealed that M15, M35, and M40 are non-specific towards 
different galanin receptor subtypes (Lu et al. 2005c) and this has limited their 
valuable contribution to delineate the galaninergic system. Still, these ligands 
have been very useful tools in the toolbox that has been used to elucidate the 
role of endogenous galanin in different systems, as well as in characterizing 
galanin receptor subtypes.  
To address the ligand selectivity problem, two galanin receptor subtype 
selective ligands, M617 and M871, were developed. The design of M617 is 
based on the sequence of M35, where an additional amino acid residue Gln was 
added to position 14. This modification resulted in 25-fold selectivity towards 
GalR1 when compared to GalR2 and agonistic activity in vitro as well as in vivo 
(Lundström et al. 2005). The design of M871 in the other hand was based on 
M40, in which the N-terminal Gly was deleted and two extra amino acid 
residues were added to the sequence. These modifications resulted in a GalR2 
antagonist (Sollenberg et al. 2006, Sollenberg et al. 2010). 
 
Table 6. The sequences of previously published galanin receptor peptide based ligands 
Name Sequence 
M15 GWTLNSAGYLLGPQQFFGLM-amide 
M35 GWTLNSAGYLLGPPPGFSPFR-amide 
M40 GWTLNSAGYLLGPPPALALA-amide 
M617 GWTLNSAGYLLGPQPGFSPFR-amide 
M871 WTLNSAGYLLGPEHPPPALALA-amide 
Gal(2–11) WTNLSAGYLL-amide 
Gal-B2 (Sar)WTLNSAGYLLGPKKK(palmitoyl)K-amide 
[N-Me,des-Sar]Gal-B2 (N-Me)WTLNSAGYLLGPKKK(palmitoyl)K-amide 
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While all these high affinity ligands are excellent tools to study the 
galaninergic system, they still exhibit several major drawbacks. First, they do 
not penetrate BBB, a major obstacle to deliver macromolecular entities, such as 
peptides, to CNS. Secondly, short half-lives and large volumes of distribution in 
the blood. In addition, they have weak selectivity towards different galanin 
receptor subtypes.  
In year 2008, a series of systemically active galanin ligands was introduced. 
In this study cationic amino acid residues and a palmitoyl moiety were used to 
increase the bioavailability and the ability to penetrate BBB of the ligands. The 
most effective analogue Gal-B2 (NAX 5055) exhibited slight selectivity 
towards GalR1 when compared to GalR2 and displayed anticonvulsant activity 
in several different animal models (Bulaj et al. 2008, White et al. 2009). Later, 
Gal-B2 was redesigned yielding a GalR2 preferring analogue with an 18-fold 
better affinity over GalR1. Similarly to Gal-B2, the novel analogue also exhibited 
anticonvulsant activity following systemic delivery (Robertson et al. 2010).  
 
Table 7. The affinities of previously published peptide based ligands for galanin 
receptors 
Name GalR1 Ki (nM) 
GalR2 
GalR3 Reference 
M15 0.65 1.0 1.0 (Smith et al. 1998) 
M35 0.11 (h) 2.0 (h) – (Borowsky et al. 1998) 
 0.325 3.24 2.09 (Smith et al. 1998) 
 4.8 8.2 4.7 (Lu et al. 2005c) 
M40 2.4 (h) 4.1 (h) – (Borowsky et al. 1998) 
 6.76 3.55 79.4 (Smith et al. 1998) 
 1.8 5.1 63 (Lu et al. 2005c) 
M617 0.23 (h) 5.7 (h) – (Lundström et al. 2005) 
 – – 49 (h) (Sollenberg et al. 2010) 
M871 420 (h) 13 (h) – (Sollenberg et al. 2006) 
 – – > 10000 (h) (Sollenberg et al. 2010) 
Gal(2–11) >5000(h) 88 271 (Lu et al. 2005b) 
Gal-B2 3.5 (h) 51.5 (h) – (Bulaj et al. 2008) 
[N-Me,des-
Sar]Gal-B2 
364 (h) 20 (h) – (Robertson et al. 2010) 
Displacement was performed on the rat galanin receptor unless indicated otherwise. (h) human; – 
not determined. 
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1.5.2. Non-peptide ligands 
Structure–activity relationships (SAR) studies have demonstrated that Trp-Asn-
Tyr in positions 2, 5, and 9 are important pharmacophores of galanin. Based on 
this information small chemical libraries were designed. Screening of the 
libraries revealed two systemically active compounds galnon (Saar et al. 2002) 
and galmic (Ceide et al. 2004). Galnon was introduced in year 2002, and is 
shown to act as a high affinity agonist for all galanin three receptor subtypes 
(Saar et al. 2002). It’s in vivo activity has been demonstrated in multiple animal 
models, including feeding (Abramov et al. 2004), anxiety and depression 
(Rajarao et al. 2007), epileptic seizure (Saar et al. 2002), and pain (Wu et al. 
2003). Galmic is shown to be GalR1 subtype specific ligand, although it has yet 
not been tested on GalR3 (Ceide et al. 2004). Despite its somewhat high 
molecular weight it penetrates BBB relatively quickly and is 6–7 times more 
potent in inhibiting self-sustaining status epilepticus (SSSE) than galnon 
(Bartfai et al. 2004). In addition, it has been demonstrated that galmic attenuates 
the immobility time of rats in FST (Bartfai et al. 2004). However, galmic and 
galnon have several major drawbacks. First, they have low affinity towards 
galanin receptors. Furthermore, it has been observed that at concentration of 10 
µM they interact with multiple important targets in CNS, i.e. 5-HT1A, D2 
dopamine, Ghreline receptors (Lu et al. 2005c).  
 
Table 8. The affinities of previously published non-peptide based ligands for galanin 
receptors 
Name GalR1 Ki (nM) 
GalR2 
GalR3 Reference 
Galnon 11700 34100 – (Saar et al. 2002) 
Galmic 34200 >100000 – (Bartfai et al. 2004) 
Sch 202596 1700 a – – (Chu et al. 1997) 
Dithiepine-
1,1,4,4-tetroxide 190
 a >30000 a – (Scott et al. 2000) 
SNAP 37889 >10000 >10000 17.4 (Swanson et al. 2005a) 
SNAP 398299 >1000 >1000 5.3 (Swanson et al. 2005a) 
GalRant >10000 >10000 15 (Barr et al. 2006) 
Displacement was performed on the rat galanin receptor unless indicated otherwise.  
a presented as IC50 values;–not determined. 
 
 
Random screening of large chemical libraries revealed couple of novel non-
peptide antagonist for galanin. Sch 202596, a GalR1 antagonist, was discovered 
from the fermentation of a fungal culture Aspergillus sp. isolated from the 
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tailing piles of an abandoned uranium mine in Tuolemene County, California. 
Sch 202596 exhibited inhibitory effect on GalR1 with an IC50 value of 1.7 µM 
(Table 8) (Chu et al. 1997). Another galanin receptor antagonist, 2,3-dihydro-2-
(4-methylphenyl)-1,4-dithiepin-1,1,4,4-tetroxide, detected from corporate 
compound collection demonstrated an IC50 value of 190 nM for GalR1 (Scott et 
al. 2000). However, its chemical reactive nature and solubility made this 
compound unattractive from a drug discovery point of view. In addition, both 
mentioned antagonist are low affinity compounds and therefore have not been 
tested in multiple animal models. 
In 2006, Konkel and colleagues published a series of 3-imino-2-indolones 
acting as high affinity antagonist for GalR3. One of them, 1,3-dihydro-1-
phenyl-3-[[3-(trifluoromethyl)phenyl]imino]-2H-indol-2-one (SNAP37889) 
was shown to have a Ki value of 17 nM (Table 8) (Konkel et al. 2006a). 
However, the published indolones demonstrated very poor aqueous solubility. 
Therefore, a series of amino analogues of 1,3-dihydro-1-phenyl-3-[[3-
(trifluoromethyl)phenyl]imino]-2H-indol-2-one were synthesized in order to 
increase the solubility and still retain the high binding affinity. This work 
resulted in a compound with an increased aqueous solubility and selectivity, 
1,3-dihydro-1-[3-(2-pyrrolidinylethoxy)phenyl]-3-[[3-(trifluoromethyl) phenyl] 
imino]-2H-indol-2-one, often referred as SNAP398299 (Konkel et al. 2006b, 
Swanson et al. 2005a). Both, SNAP398299 and SNAP37889, have been 
effectively tested in various in vivo models. Later, Barr and colleagues 
introduced another indolone based GalR3 antagonist, 3-(3,4-dichloro-
phenylimino)-1-(6-methoxypyridin-3-yl)indolin-2-one, and also demonstrated 
its activity in preclinical tests (Barr et al. 2006). Taken together, these studies 
suggest that GalR3 antagonist have anxiolytic- and antidepressant-like effects 
(Swanson et al. 2005a, Barr et al. 2006). 
In 2010, the first GalR2-positive allosteric modulator CYM2503 was 
characterized in The Scripps Research Institute (Lu et al. 2010). CYM2503 was 
demonstrated to stimulate IP production in HEK293 cells stably expressing 
GalR2 receptors, while showing no detectable affinity for GalR2. CYM2503 
exhibited anticonvulsant activity upon i.p. administration in acute seizure 
models in rats and mice. One year later, in the same institute small molecular 
2,4,6-triaminopyrimidine derivatives were designed and tested on GalR1 and 
GalR2. A series of them were shown to bind GalR2 with an IC50 value ranging 
from 0.33 to 1.0 µM (Sagi et al. 2011). 
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2. AIMS OF THE STUDY 
Neuropeptide receptors are currently of high interest as a class of drug targets 
for the pharmaceutical industry. However, the precise role of different galanin 
receptor subtypes in various human diseases and pathological conditions is still 
not fully understood due to the lack of galanin receptor subtype specific ligands. 
Therefore, the research presented in this thesis is mainly focusing on the 
development of novel subtype specific ligands, and evaluating their biological 
effect in behavioral models. The main aims of the respective papers are 
presented below: 
 
Paper I. The main objective in this paper is to develop a novel GalR2 subtype 
specific ligand, and to introduce a stable hGalR3 cell line that is 
useful for the characterization of future galanin ligands. 
 
Paper II. The aim of this paper is to introduce several novel GalR2 selective 
agonists, and to compare the most selective one with a known GalR1 
selective agonist M617 for their ability to stimulate acute 
consumption of several foods.  
 
Paper III. The objective within this publication is to develop a novel highly 
subtype specific GalR2 agonist, and to compare its ability with an 
antidepressant medication imipramine to attenuate depression-like 
behavior in tail suspension test. 
 
Paper IV. The aim of this study is to design an approach to increase in vivo 
usability of peptide ligands, and to develop a series of systemically 
active novel GalR ligands with preferential binding towards GalR2. 
Furthermore, the ability of the novel ligands to attenuate depression-
like behavior in several different animal models is compared with a 
common clinically used antidepressant medication imipramine. 
Moreover, Paper IV includes an in-depth characterization of one of 
these peptide ligands. 
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3. METHODOLOGICAL CONSIDERATIONS 
3.1. Solid phase peptide synthesis 
All peptides used in this thesis were synthesized using solid phase peptide 
synthesis (SPPS) . The introduction of the SPPS technique by Bruce Merrifield 
in 1963 was a big breakthrough in peptide synthesis methodology (Merrifield 
1963). It dramatically changed the strategy of peptide synthesis and simplified 
the steps of purification. The principle of SPPS is based on repeated cycles of 
coupling and deprotection of protected amino acids, carried out on an insoluble 
support, resin.  
The peptides that have been used within this thesis were synthesized using 
small scale (0.1 mmol) 9-fluorenylmethyloxycarbonyl (Fmoc) solid-phase 
peptide synthesis strategy on an automated peptide synthesizer (Applied Bio-
systems™ model 433A). Fmoc amino acids were coupled as hydroxybenzo-
triazole (HOBt) esters to a p-methylbenzylhydrylamine (MBHA) resin (Fluka), 
which will generate a C-terminally amidated peptide after the final cleavage. 
The peptides were finally cleaved from the resin using 95% TFA (trifluo-
roacetic acid), 2.5% TIS (triisopropylsilane), and 2.5% H2O solution for 3 h. 
To obtain branched peptides (Paper II and IV) with Glu or stearic acid 
substitution amino acid residue Fmoc-Lys(Mtt)-OH (Iris Biotech GMBH, 
Germany) was used. 4-methyltrityl(Mtt) – protecting group was removed 
manually by using 1% TFA, 2% TIS solution in DCM (dichloromethane). 
Stearic acid was coupled as a hydroxybenzotriazole (HOBt) ester overnight. 
All the peptides were purified by reverse-phase HPLC using Nucleosil  
120–3 C-18 column (SP 250/10 Nucleosil Macherey-Nagel, Germany), and the 
correct molecular weight was determined by Perkin Elmer prOTOF™ 2000 
matrix assisted laser desorption ionization time-of-flight mass spectrometry 
(Perkin Elmer, Sweden). 
 
 
3.2. Galanin receptor ligands (Papers I–IV) 
In paper I, the design of M1145 is based on a previously published chimeric 
ligand M871, the GALP peptide and its preferences towards GalR2, and the fact 
that the deletion of the Gly residue on the N-terminus of galanin yields in 
selectivity towards GalR2. For M1145, the galanin sequence 1–13 was 
elongated with six amino acid residues from the GALP sequence, four amino 
acid residues N-terminally (RGRG) and two amino acid residues C-terminally 
(VL). The Gly residue in the N-terminus of galanin (deleted in M871) was 
replaced with an Asn to disturb binding towards GalR1 and potentially also to 
GalR3. M1145 also contains the C-terminal portion of the GalR2 selective 
ligand M871; Pro-Pro-Pro-(Ala-Leu)2-Ala and the C-terminal amide 
(Sollenberg et al. 2006, Ohtaki et al. 1999). 
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In paper II, we evaluate M1151, a previously published peptide by Pooga 
and colleagues in a study where they introduced a series of peptide ligands with 
different compounds that have been added orthogonally to the side chain of Lys 
residue in position 14 (Pooga et al. 1998). In addition, we also introduce two 
novel peptide ligands, M1152 and M1153. Both ligands are identical with 
M1151 in the C-terminal part of the sequence, but have different modifications 
in the N-terminus. In M1152, similarly with M871, the Gly residue in position 1 
is deleted, whereas in M1153, in analogy with M1145, the N-terminal part is 
elongated with four amino acids (RGRG) and the Gly in the N-terminus is 
substituted with Asn (Sollenberg et al. 2006, Runesson et al. 2009). All these 
modification were introduced in order to improve the selectivity of the ligands 
towards GalR2. 
Paper III demonstrates a highly subtype specific GalR2 ligand M1160. The 
design of M1160 is based on the sequence of M1145 (Runesson et al. 2009), in 
which the amino acid residue Thr was deleted from the position 6 in order to 
decrease binding towards GalR3. The relevance behind this strategy is based on 
previous research indicating that Thr plays an important role when binding to 
GalR3, but is not crucial when binding to other GalR subtypes (Runesson et al. 
2010b, Church et al. 2002, Kask et al. 1998, Lundström et al. 2007). 
In paper IV, we introduce a series of systemically active novel GalR ligands 
(J17-J21) with preferential binding towards GalR2. The design of these ligands 
was based on M1145 and M1153 (Runesson et al. 2009, Saar et al. 2011). 
Similarly to M1153 and M1145, the N-terminus of J17-J21 was elongated with 
four amino acids residues (RGRG) from GALP sequence and the Gly in 
position 5 was substituted with Asn (Lundström et al. 2007, Runesson et al. 
2009, Saar et al. 2011). In addition, to increase the pharmacokinetic properties 
and the CNS activity of the ligands a stearoyl acid was coupled to the side chain 
of the Lys in the C-terminal part of the peptides. Furthermore, the C-terminal 
part was elongated with additional positively charged amino acids. In the 
peptide J18, the three C-terminally positioned L-Lysins were substituted to  
D-Lysins in order to reduce enzymatic degradation and further increase the 
bioavailability. 
 
 
3.3. Radioligand binding assay (Paper I–IV) 
Radioligand binding assays are often used in pharmacological research in order 
to study receptor systems. In this thesis, competitive binding assay was 
performed to screen the binding properties of novel galanin receptor ligands to 
their target receptors, GalR1-GalR3. In this assay, the concentration of the 
radioligand is held constant throughout the experiment, while various con-
centrations of the ligand are added. Thereafter, the ability of the radioligand to 
bind the receptor in the presence of the unlabeled ligand is measured and the 
IC50 is calculated. IC50 presents the concentration of the unlabeled compound 
9
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where it produces 50% of the specific binding of the radioligand. However, the 
IC50 value depends on the radioligand concentrations that might vary between 
experiments. Therefore, this value is converted using Cheng-Prusoff equation 
into Ki value.  
Porcine 125I-galanin was used as the radioligand. It is the most commonly 
used radioligand in field, since radiolabeling of galanin is performed through 
the iodiation of Tyr, and porcine galanin is the only known endogenous galanin 
sequence that possesses an extra Tyr. Although human 125I-galanin is available, 
it is rarely used due to its labeling of Tyr in position 9, the residue that is known 
to be important for ligand-receptor interactions (Land et al. 1991a).  
Throughout this thesis silanized plastic was used to minimize the binding of 
the peptides to the plastic. Additionally, polyethyleneimine (PEI) was used to 
minimize adsorption to the glass fiber in order block unspecific binding.  
 
 
3.4. Inositol phosphate accumulation (Paper I–III) 
Previous research has shown that GPCR Gq stimulation leads to activation of 
phospholipase c (PLC) and triggers inositol phosphate cascade. Therefore, 
inositol phosphate (IP) accumulation assay can be used to measure the 
activation of Gq-proteins. The assay is based on the detection of tritium labeled 
IP that is accumulated in the cells following the stimulation of the Gq receptor. 
Despite the fact that this protocol is relatively insensitive and time consuming 
the method has been widely used in galanin research.  
In this assay, the cells were labeled with 3H-myoinositol, a radiolabel which 
incorporates into phosphatidylinositol 4,5-bisphosphate (PIP2) and thereafter 
into its hydrolyzed product IP3 and its downstream metabolics. IP recycling into 
myo-inositol was blocked by adding Lithiumchloride (LiCl). The inositol 
phosphates, including IP3 and its downstream metabolics inositol 4,5-
bisphosphate (IP2) and IP, were extracted in the presence of perchloric acid and 
separated by an anion exchange column. The total radioactivity was measured 
by a β-counter and normalized to the total count in each sample.  
 
 
3.5. Depression-like behavior (Paper III–IV) 
Since depression is a complex disorder, it is very difficult to develop an animal 
model that would be able to mimic all the symptoms of depressed patients. 
Moreover, some of the symptoms are impossible to model in rodents. However, 
before starting complex and expensive preclinical trials the initial screening of 
novel compounds with antidepressant properties requires a simple and rather 
robust model. Therefore, several test procedures have been developed, including 
the tail suspension test (Steru et al. 1985), the forced swim test (Porsolt et al. 
1977), the learned helplessness model (Seligman & Maier 1967), and the 
chronic mild stress (Willner 1997). Within this thesis, two of the mentioned 
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models, the forced swim test (FST) and the tail suspension test (TST), were 
used to test novel galanin receptor subtype specific ligands for their ability to 
attenuate depression-like behavior, and to show their agonistic properties in 
vivo. Both, FST and TST, are based on the same principle: animals are 
subjected to a short-term inescapable period of stress and the time of immobility 
is measured.  
 
 
3.5.1. Tail suspension test 
For this test, mice were individually suspended to the wooden beam by the tail, 
using adhesive tape that has been applied 1 cm from the end of the tail, for a 6-
minute period. The duration of immobility during the last 4 minutes was 
measured. Immobility was defined as complete lack of movements beside 
respiration. 
 
 
3.5.2. Forced swim test 
The FST consisted of one episode of 6 minutes swimming (glass container, 
diameter 15 cm, height 30 cm), of which the last 4 minutes were scored for total 
immobility time. Similarly to TST, the duration of immobility during the last 4 
minutes was measured. Immobility was defined as complete lack of movements 
beside respiration. 
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4. RESULTS AND DISCUSSION 
All four studies presented within this thesis are focusing on the development of 
novel galanin receptor subtype specific ligands. Besides, the first study also 
presents the development and characterization of an inducible GalR3 cell line. 
In the second study the ability of GalR1 and GalR2 agonists to stimulate acute 
food consumption in mice has been compared, whereas the focus in the third 
paper consisted in demonstrating the ability of a novel GalR2 agonist (M1160) 
to attenuate depression-like behavior in TST. Finally, the fourth study presents 
an approach on how to increase the in vivo usability of peptide ligands. It also 
demonstrates the ability of several novel systemically active GalR2 preferring 
ligands to attenuate depression-like behavior in a side by side comparison with 
the clinically used antidepressant imipramine in different animal models.  
 
 
4.1. Novel galanin subtype selective ligands  
(Paper I–IV) 
The importance of galanin receptor subtype specific ligands in delineating the 
galanin system cannot be overestimated. As the galaninergic system remains a 
promising drug target, the information about galanin receptor subtype mediated 
effects is of high importance. The main objective of this thesis is to develop 
tools that contribute to the characterization of the galaninergic system, thus 
designing and characterizing novel GalR2 subtype specific ligands using 
various approaches.  
Paper I demonstrates the design and characterization of a novel galanin 
analogue M1145 with selectivity towards GalR2, compared to GalR1 and 
GalR3 (Table 10). The design of M1145 was based on extending the N-terminal 
part of the galanin analogue. In addition, this study also examines the signaling 
of M1145 through Gq, the preferential G-protein for the GalR2. M1145 showed 
increased IP production in a similar manner with galanin (Table 9). Further-
more, M1145 also demonstrated an additive effect on signal transduction in the 
presence of galanin. Taken together, Paper I presents a novel GalR2 subtype 
specific ligand with agonistic properties.  
Paper II presents one previously published and two novel (M1152 and 
M1153) galanin receptor subtype specific ligands. This design of the C-terminal 
part of the peptides was based on an article by Pooga and colleagues, where 
several different compounds were orthogonally added to the side chain of the 
Lys residue situated at position 14 and tested for binding affinity on receptors 
isolated from rat hypothalamic tissues (Pooga et al. 1998). In contrast to 
Pooga`s paper, the binding assays in this current study were performed on 
membranes from three different cell lines, each expressing a single galanin 
receptor subtype. This was done in order to examine the subtype specificity of 
the ligands.  
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Table 9. Galanin receptor ligand studied in this thesis 
Name Sequence 
Rat galanin GWTLNSAGYLLGPHAIDNHRSFSDKHGLT-amide 
M1145 RGRGNWTLNSAGYLLGPVLPPPALALA-amide 
M1151 GWTLNSAGYLLGPK(ε-NH-C(O)(CH2)2C(NH2)COOH)-amide 
M1152 WTLNSAGYLLGPK(ε-NH-C(O)(CH2)2C(NH2)COOH)-amide 
M1153 RGRGNWTLNSAGYLLGPK(ε-NH-C(O)(CH2)2C(NH2)COOH)-amide 
M1160 RGRGNWLNSAGYLLGPVLPPPALALA-amide 
J17  RGRGNWTLNSAGYLLGPKKK(εNH·C(O)stearic acid)-amide 
J18 RGRGNWTLNSAGYLLGPkkK(εNH·C(O)stearic acid)k-amide 
J19 RGRGNWTLNSAGYLLGPOOK(εNH·C(O)stearic acid)O-amide 
J20 RGRGNWTLNSAGYLLGPXXK(εNH·C(O)stearic acid)K-amide 
J21 O1GO1GNWTLNSAGYLLGPO1O1K(εNH·C(O)stearic acid)O1-amide 
X – 6-aminohexanoic acid. O1 – Ornithine 
 
 
M1151(Pooga et al. 1998) demonstrated rather unselective binding properties 
with somewhat preferential binding towards GalR2 when compared to GalR1 
and GalR3 (Table 19). Therefore, to improve the preferential GalR2 binding 
M1151 was modified either by extension of the N-terminus (M1153) or by 
deletions in the N-terminus (M1152). The deletion of the N-terminal Gly 
residue in M1152 in analogy with previously designed M871 (Sollenberg et al. 
2006) resulted in increased subtype selectivity, but also in a two-fold lower 
affinity towards GalR2. The design of M1153 was based on the previously 
published M1145 (Runesson et al. 2009). Similarly to M1145, the N-terminal 
part of M1153 was elongated with four amino acid residues (RGRG) from the 
galanin-like peptide (GALP) sequence (Ohtaki et al. 1999, Runesson et al. 
2009), and the N-terminal Gly was substituted with an Asn in order to disturb 
binding to GalR1 and GalR3 (Runesson et al. 2009, Sollenberg et al. 2006). 
M1153 exhibited a noticeably higher selectivity than previously published 
ligands for GalR2, and still retained high binding affinity, comparable with the 
affinity of galanin, for GalR2. One could speculate that the improved binding 
affinity of M1153 could be explained by the possibility that Glu in the side 
chain of Lys can form additional hydrogen bonds, which may contribute to the 
interactions with GalR2. The observed lower binding affinity of M1151, 
M1152, and M1153 towards GalR3 could be due to the orthogonally coupled 
Glu, since GalR3 has been proposed to have a relatively narrow binding pocket 
compared to GalR2 (Runesson et al. 2010a, Jurkowski et al. 2013).  
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Table 10. The affinities of novel ligands presented in this thesis 
Name GalR1 Ki (nM) 
GalR2 
GalR3 Ki (GalR1) / 
Ki (GalR2) 
Ki (GalR3) / 
Ki (GalR2) 
Rat galanin 1.75 a 2.98 a 4.49 a 0.6 1.5 
M1145 587 a 6.55 a 497 a 90 76 
M1151 98.6 b 28.9 b 874 b 3.4 30 
M1152 2370 b 36.4 b 656 b 65 18 
M1153 1890 b 4.98 b 230 b 380 46 
M1160 15500 c 33.3 c > 10000 c 465 c >1000 c 
J17  156 d  29 d 125 d 5.4 d 4.3 d 
J18 138 d 20 d 112 d 6.9 d 5.6 d 
J19 231 d 83 d 114 d 2.8 d 1.4 d 
J20 25 d 4.9 d 13 d 5.1 d 2.7 d 
J21 138 d 41 d 65 d 3.4 d 1.6 d 
a Paper I, b Paper II, c Paper III, d Paper IV 
 
 
As in paper I, the agonistic effect of M1153 was assessed by measuring IP 
accumulation. M1153 exhibited a clear dose dependent increase in IP 
production, whether administered alone or together with galanin.  
Paper III demonstrates a highly subtype specific GalR2 ligand M1160 
with  5̴00-fold selectivity (Table 10). Design of M1160 was based on M1145 
(Paper I) and previously published mutagenesis studies indicating that Thr has 
an important role to play in binding to GalR3, but not to such a degree when 
binding to other two galanin receptor subtypes. The proposed theory states that 
Thr forms hydrogen bonds and stabilizes the binding conformation through 
vdW interactions when binding to GalR3 (Kask et al. 1998, Runesson et al. 
2010a, Church et al. 2002, Lundström et al. 2007). The deletion of Thr from the 
6th position of M1145 sequence abrogated the ability of M1160 to bind GalR3 
at all. In addition, it also resulted in a tremendous loss of binding affinity 
towards GalR1 (Table 10). The truncation of Thr also led to a small loss of 
affinity towards GalR2, although still showing a relatively high Ki value 
towards GalR2. Similarly to M1145 (Paper I) and M1153 (Paper II), M1160 
also expressed agonistic properties in vitro, which were assessed by its ability to 
stimulate IP production. A dose-dependent additive effect of signal transduction 
in the presence of 10 nM galanin was also seen. Taken together, this study 
presents a GalR2 subtype specific agonistic ligand that compared to previously 
published ligands such as M1153, galanin(2–11), and M1145 exhibited 
noticeably higher selectivity. 
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As suggested earlier, peptide mimics have a number of disadvantages when 
considering their drugability. First, their short half-lives due to enzymatic 
degradation and large volumes of distribution in the blood are a concern. 
Secondly, blood brain barrier (BBB) is a major obstacle when delivering 
macromolecular entities, such as peptides, to CNS. Paper IV addresses these 
issues by presenting an approach to increase in vivo usability of peptide ligands 
and demonstrates a series of systemically active novel GalR ligands, J17-J21 
with preferential binding towards GalR2. The design of these ligands was based 
on two previously published GalR2 agonists M1145 and M1153. The  
N-terminal part of the novel ligands were elongated with the same four amino 
acid residues (Arg-Gly-Arg-Gly) that are present in the galanin-like peptide 
(GALP), as was done in case of M1145 and M1153. In order to disturb the 
ligand binding to GalR1 and GalR3 the N-terminal Gly in position 5 was 
replaced with Asn. To improve the pharmacokinetic properties (i.e. stability to 
degradation) and the CNS activity of the ligands, two commonly known 
strategies were used. First, the ligands were elongated with additional positively 
charged amino acids (cationization) (Witt & Davis 2006). Secondly, a stearic 
acid was coupled to the side chain of the C-terminal Lys of the ligands 
(lipidization) (Dasgupta et al. 2002). Both cationization and lipidization have 
shown to enhance the bioavailability of the peptides in the brain (Bulaj et al. 
2008). Additionally, several L-amino acids in one of the ligands (J18) were 
replaced with D-amino acids to reduce enzymatic degradation and further 
increase the bioavailability. These modifications resulted in a slight loss of 
subtype specificity for GalR2 and in a decrease of binding affinity when 
compared to previously published GalR2 agonists M1145 and M1153 (Table 
10). Nevertheless, all the tested peptides still exhibited a noticeable preferential 
binding towards GalR2. Furthermore, the biodistribution comparison of J18 
with a previously published peptide M1145 clearly showed a much higher half-
life of J18, which reflects in its higher stability to degradation. The levels of J18 
were higher in all organs 1h and 3h post-injection in mice. At 24h post-
injection, J18 had been cleared out from the organism, while M1145 had 
already been largely eliminated after 3h. In addition, the levels of J18 in the 
brain were 2.5 fold higher than that of M1145. These results suggest that the 
combination of increased stability and lipofilicity improved the ability of J18 to 
penetrate the BBB. 
As mentioned before, ligands presented in Paper IV have somewhat 
decreased binding affinity and lower receptor subtype selectivity when 
compared to their forerunners. However, this may not always indicate anything 
about the usefulness of the peptides in vivo, because increased stability might 
compensate for lower affinity. Although, establishing high subtype selectivity 
ligands in conjunction with high binding affinity is of great interest.  
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4.2. Galanin in feeding regulation 
As described previously, galanin plays a critical role in regulation of energy 
homeostasis. Previous research has shown that galanin has an immediate and 
robust effect on stimulation of food intake following the administration into the 
ventricle or PVN (Crawley et al. 1990, Kyrkouli et al. 1986, Kyrkouli et al. 
1990, Leibowitz 2005). All three galanin receptor subtypes can be found in the 
hypothalamic region (Waters & Krause 2000), and therefore can mediate this 
effect. Paper II provides the first side-by-side comparison of highly galanin 
receptor-selective agonists on feeding behavior. Two of the evaluated subtype 
selective agonists M1153 and M1145 were shown to have no effect on the acute 
consumption of two highly palatable foods. In contrast, the GalR1 selective 
agonist M617 notably stimulated acute consumption of high-fat milk. These 
results are in concordance with previous research suggesting that galanin 
increases food intake through GalR1 (Lundström et al. 2005). Another study 
reported that galanin fragment Gal(2–29) has no effect on feeding, which is 
consistent with the results in the present study. Moreover, GalR1 knockout mice 
showed abnormal adaptation responses to dietary challenges of high fat and 
high glucose conditions, while normal regulation was seen on low fat and chow 
diets (Holmes et al. 2003b, Zorrilla et al. 2007, Wrenn et al. 2004). GalR2 
knockout mice on the other hand demonstrated no differences in feeding 
behaviors or body weights (Gottsch et al. 2005). In summary, Paper II, in 
concordance with previous research, indicates that the GalR1 is most involved 
in the regulation of feeding.  
 
 
4.3. Galanin in depression-like behavior 
Galanin is known to play an important role in the regulation of mood disorders. 
Previous research has shown that different galanin receptor subtypes have 
distinct functions in regulating depression. Activation of GalR1 and GalR3 is 
suggested to result in a depression-like behavior, while stimulation of GalR2 
leads to attenuation of the same behavior (Kuteeva et al. 2008a). Based on this 
information Paper III and IV test the potential agonistic properties of novel 
peptide ligands in vivo by using different animal models in order to evaluate 
their effects on antidepressant behavior.  
Although previous research has shown evidence that stimulation of GalR2 
leads to attenuation of depression-like behavior, Paper III is the first study 
demonstrating the same effect using a highly GalR2 subtype specific ligand. In 
this study TST, a common rodent model for depression-like behavior, was used 
to evaluate the effects of the tested compounds on antidepressant behavior. 
Both, M1160 and Imipramine, presented significant decrease in the immobility 
time when compared to the saline group. In summary, Paper III demonstrates 
agonistic and antidepressant properties of M1160.  
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Within Paper IV the involvement of systemically active GalR2 subtype 
preferring ligands in depression like-behavior were assessed in two different 
animal models (TST and FST) using different administration techniques. I.v. 
administration of several peptide ligands reduced the immobility time in FST. 
In the current study the highest effect was obtained by the peptide J18. It was 
comparable to the effect attained by the clinically relevant antidepressant 
imipramine. Remarkably, the effective doses of J18, 0.5 mg/kg and 0.25 mg/kg 
are equal to 192 nmol/kg and 96 nmol/kg, which reflect the strikingly high 
potency of the peptides. 
As mentioned above, another model (TST) was used to further confirm the 
systemic activity of the novel peptides. As expected, similarly to the effect in 
FST, J18 exhibited potent systemic activity in TST. In addition, Paper IV shows 
that the antidepressive effect of J18 is also retained via the i.p. administration 
route, which is of high importance for animal studies, as it permits easy, stress-
free handling and enables an experimental setup with chronic administration. 
Antidepressive drug screening animal models utilize acute administration of a 
drug (2 injections for rats and 1 injection for mice in TST or FST). However, it 
is generally known that chronic administration for 2–4 weeks is required for 
SSRIs to see antidepressive effect in clinics. Therefore, this current study 
investigated the possibility to use J18 in other depression models, which utilize 
repeated administration of a drug, because different feedback mechanisms or 
receptor desensitization may decrease the pharmacological potency of the 
compound. Chronic administration of J18 still retained its antidepressant-like 
effect in TST, suggesting that further characterization of J18 and other currently 
presented peptides in different models is possible.  
Furthermore, to verify that galanin receptors mediate all the effects seen with 
J18, a non-selective galanin receptor antagonist M35 (i.c.v) was used con-
comitantly with J18 (i.p.). In agreement with our hypothesis, M35 blocked the 
effect induced by i.p. injected J18.  
Taken together, Paper III and IV demonstrate in vivo agonistic properties of 
a series of GalR2 subtype preferring ligands. In addition, in accordance with 
previous research these current studies confirm that stimulation of GalR2 leads 
to attenuation of depression-like behavior. Previously, Kuteeva and colleagues 
tested GalR2(R3) agonist AR-M1896 and GalR2 antagonist M871 to demon-
strate GalR2 involvement in depression-like behavior in FST. AR-M1896, 
similarly with fluoxetine, showed decreased values in immobility time, and 
M871 increased the immobility time in the FST (Kuteeva et al. 2008b). Similar 
results have been obtained using galanin antagonist to block the effect of 
fluexetine in FST, suggesting that the effect of fluoxetine treatment at least 
partially involves galanin related transmission (Lu et al. 2005a).  
However, as depression is a complex and multifactorial disorder, more 
studies have to be carried out in order to confirm the antidepressant like actions 
of these ligands. Several different and more complex behavioral models of 
11 
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depression should be tested in parallel with measurements of other functions 
that are confounds in the models of depression. 
 
 
4.4. Development of GalR3 inducible cell line 
Paper I introduces the development of a novel GalR3 inducible cell line, a well 
appreciated tool expanding the possibilities of characterizing galanin receptor 
ligands.  
More specifically, a stable Flp-In T-Rex cell line with an inducible expres-
sion of hGalR3 was developed and characterized. Western Blot analysis 
confirmed a clear induction of the GalR3 expression after 24 and 48 h treatment 
with tetracycline, while showing no expression of GalR3 protein in non-induced 
cells. Displacement binding studies on GalR3 expressing membranes using 
galanin and a GalR3 selective antagonist SNAP37889 demonstrated their ability 
to inhibit 125I-galanin binding, thus confirming the presence of GalR3 receptor. 
Furthermore, in the functional GTPγ assay on GalR3 expressing membranes rat 
galanin stimulated GTPγ activity over 75% of the basal activity. In the same 
setting SNAP37889 exhibited no effect, but inhibited dose-dependently the 
GTPγ activity induced by 1 µM galanin. Additionally, homologues competitive 
binding calculations showed that the protein expression level in Flp-In T-Rex 
GalR3 membranes corresponds to two other cell systems used in this thesis, 
indicating that the cell systems used in the current study are highly compatible.  
Taken together, Paper I presents a novel GalR3 inducible cell line, which 
functional properties are in line with previous studies performed on human 
GalR3 (Branchek et al. 2000). 
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5. CONCLUSIONS AND FUTURE PROSPECTS 
The main conclusions of the four papers comprising this thesis are presented 
below. 
 
Paper I. A novel GalR2 subtype specific peptide M1145 was designed and 
characterized. It exerted agonistic properties in vitro by assessing its 
ability to stimulate IP production. In addition, a stable GalR3 cell 
line was developed, providing a new tool for characterization of 
future galanin ligands. 
 
Paper II. Extension of the N-terminal part and replacement of a N-terminal 
Gly with Asn leads to higher receptor subtype specificity (M1153). 
Side by side comparison of GalR1 and GalR2 agonists suggests that 
galanin induced increased food intake is mediated through GalR1. 
 
Paper III. Deletion of amino acid residue Thr from position 6 of M1145 
(Paper I) led to a discovery of a highly subtype specific GalR2 
ligand with agonistic properties. Additionally to in vitro studies, 
i.c.v. administered M1160 also demonstrated agonistic properties in 
vivo by attenuating depression-like behavior in a similar manner 
with Imipramine. 
 
Paper IV. Introduction of a stearoyl moiety and additional positively charged 
amino acids to the C-terminal part of the M1153 (Paper II) sequence 
resulted in a series of GalR2 subtype preferring ligands with 
increased stability to enzymatic degradation and penetration to brain. 
Furthermore, these ligands exhibit potent antidepressant effect at 
notably low doses in several common rodent screening models of 
depression-like behavior. 
 
 
In conclusion, this thesis provides a number of different novel galanin receptors 
binding ligands. Simultaneously, it demonstrates multiple different design 
strategies and chemical modifications that increase the binding and signaling 
properties, decrease susceptibility towards enzymatic degradation, and improve 
penetration to the brain. Additionally, this study provides a stable GalR3 cell 
line, a novel tool improving the possibilities for the characterization of galanin 
analogues. Furthermore, the results of this thesis have led to the hypothesis that 
GalR2 agonists could potentially be used as a treatment for mood disorders, and 
GalR1 antagonists might yield as drugs for acute suppression of appetite. 
However, in both cases further studies using more relevant and complex animal 
models need to be carried out.  
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Even though numerous peptide based ligands for galanin receptors have 
been produced during the last years, the field still lacks highly subtype specific 
ligands that could be administered systemically. As galanin is known to regulate 
numerous pathological and physiological processes it has become an obvious 
drug target. Thus, the validation of galanin receptors as drug targets is of great 
interest. So far, the use of transgenic animals and modern molecular biology has 
led the field in delineating the involvement of different receptors in various 
diseases. However, the caveat of using KO animals is the tendency of organisms 
to result in neurochemical compensatory mechanisms when lifelong genetic 
alterations are being made. Therefore, highly subtype specific and systemically 
active galanin receptor ligands would be extremely helpful in mapping the 
galaninergic system, and could potentially be used as treatment for several 
different diseases. Within this thesis we presented a series of systemically active 
peptides. Nevertheless, there is still a big obstacle to overcome, since even 
minor changes in the sequence of the peptide tend to decrease its binding 
properties and subtype specificity. Hopefully, in parallel with the continuous 
development of novel ligands, research will provide the field with X-ray 
structures for galanin receptors or galanin receptor-ligand complexes. This 
would rapidly advance the field and make the development of novel ligands 
easier by applying structure based ligand design.  
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6. SUMMARY IN ESTONIAN 
Uudsed GalR2 spetsiifilised ligandid: nende mõju toitumisele 
ning depressiooni-laadsele käitumisele 
Galaniin on 29 aminohappe pikkune neuropeptiid, mis avastati ligi 30 aastat 
tagasi Stockholmis, Karolinska Instituudis Viktor Muti ja tema kolleegide poolt. 
Galaniin reguleerib kolme spetsiifilise G-valguga seotud retseptori (GPCR) 
alatüüpide (GalR1-GalR3) interaktsioonide abil mitmeid bioloogilisi funkt-
sioone nagu depressioon, ärevus, alkoholisõltuvus, ainevahetuse häired ja valu. 
Kõik kolm retseptori alatüüpi on galaniini suhtes kõrge afiinsusega, omades 
seejuures erinevaid funktsionaalseid omadusi ja signaaliülekande radasid. 
Seetõttu on neil täita erinevad ülesanded mitmesuguste haiguste ja patoloogi-
liste seisundite reguleerimisel, muutes galaniini ja tema spetsiifilised retseptorid 
olulisteks farmakoloogia märklaudadeks ning uurimisobjektideks neuro-
teaduses. Hoolimata sellest on retseptorite alatüüpide seotus erinevate haigus-
tega senini täielikult määratlemata, mis on suurel määral põhjustatud galaniini 
retseptorite alatüüp-spetsiifiliste ligandide puuduse tõttu.  
Käesoleva doktoritöö peamiseks eesmärgiks on galaniini alatüübile 2 
(GalR2) spetsiifiliste ligandide disainimine, süntees ja omaduste uurimine nii in 
vitro kui ka in vivo tingimustes. 
Täpsemalt, publikatsioonis I kirjeldatakse uudse GalR2 ligandi M1145 
disaini, määratakse ligandi afiinsus galaniini membraansete retseptorite suhtes 
ja näidatakse M1145 võimet aktiveerida Gαq/11-valgu poolt reguleeritavat 
signaaliülekande rada. Lisaks demonstreeritakse uudset rakuliini, mis toodab 
GalR3 ja on abiks uute ligandide omaduste iseloomustamiseks. Publikatsiooni-
des II ja III sünteesiti, sarnaselt esimesele, rida galaniini analooge ja määrati 
nende afiinsus erinevate galaniini retseptorite alatüüpide suhtes. Lisaks kasutati 
loodud ligande GalR2 aktiveerimise mõju demonstreerimiseks toitumisele ning 
depressiooni-laadsele käitumisele. Publikatsioonis IV kirjeldatakse meetodit, 
kuidas suurendada peptiidsete ligandide stabiilsust ensümaatilise lagundamise 
suhtes ning võimet läbida aju-vere barjääri. Rakendades kirjeldatud metoodikat, 
sünteesiti rida uudseid galaniini analooge ning demonstreeriti seejuures nende 
võimet vähendada depressiooni-laadset käitumist erinevates loommudelites.  
Kokkuvõtvalt, käesolevas doktoritöös esitletakse mitmeid strateegiaid uud-
sete ja samas süsteemselt toimivate GalR2 selektiivsete peptiidsete ligandide 
disainiks. Uudseid ühendeid on tulevikus võimalik kasutada erinevate galaniini 
retseptorite alatüüpide rolli määramiseks mitmesugustes haigustes. Lisaks 
uuritakse töös GalR2 seost depressiooni-laadse käitumise ning toitumisega, 
demonstreerides seejuures mõnede ligandide võimet vähendada depressiooni-
laadset käitumist, sarnaselt laialdaselt kliinilises kasutuses oleva antidepressandi 
imipramiiniga.  
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